Evidence map›Paper›PMID 30143934›Full record

ArticleInflammation2018

Protective Effect of 2-Hydroxymethyl Anthraquinone from Hedyotis diffusa Willd in Lipopolysaccharide-Induced Acute Lung Injury Mediated by TLR4-NF-κB Pathway.

Jiani Tan, Liu Li, Wenjing Shi, Dongdong Sun, Changliang Xu, Yunjie Miao, Huisen Fan, Jianrong Liu, Haibo Cheng, Mianhua Wu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Can natural products modulate cytokine storm in SARS-CoV2 patients?Biotechnology reports (Amsterdam, Netherlands) · 2022
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jiani TanTranslational Medicine Research Center, Nanjing University of Chinese Medicine, No. 138, Xianlin Road, Nanjing, Jiangsu, People's Republic of China.
Liu LiTranslational Medicine Research Center, Nanjing University of Chinese Medicine, No. 138, Xianlin Road, Nanjing, Jiangsu, People's Republic of China.
Wenjing ShiTranslational Medicine Research Center, Nanjing University of Chinese Medicine, No. 138, Xianlin Road, Nanjing, Jiangsu, People's Republic of China.
Dongdong SunTranslational Medicine Research Center, Nanjing University of Chinese Medicine, No. 138, Xianlin Road, Nanjing, Jiangsu, People's Republic of China.
Changliang XuTranslational Medicine Research Center, Nanjing University of Chinese Medicine, No. 138, Xianlin Road, Nanjing, Jiangsu, People's Republic of China.
Yunjie MiaoTranslational Medicine Research Center, Nanjing University of Chinese Medicine, No. 138, Xianlin Road, Nanjing, Jiangsu, People's Republic of China.
Huisen FanTranslational Medicine Research Center, Nanjing University of Chinese Medicine, No. 138, Xianlin Road, Nanjing, Jiangsu, People's Republic of China.
Jianrong LiuTranslational Medicine Research Center, Nanjing University of Chinese Medicine, No. 138, Xianlin Road, Nanjing, Jiangsu, People's Republic of China.
Haibo ChengTranslational Medicine Research Center, Nanjing University of Chinese Medicine, No. 138, Xianlin Road, Nanjing, Jiangsu, People's Republic of China. chbnucm@163.com.
Mianhua WuJiangsu Province Hospital of TCM, Affiliated Hospital of Nanjing University of TCM, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Weixing ShenTranslational Medicine Research Center, Nanjing University of Chinese Medicine, No. 138, Xianlin Road, Nanjing, Jiangsu, People's Republic of China. wxshnjucm@163.com.
Jiangsu Province Hospital · CNNanjing University of Chinese Medicine · CN

Funding

National Natural Science Foundation of China 81373511National Natural Science Foundation of China 81403079National Natural Science Foundation of China 81573910National Natural Science Foundation of China 81673559Natural Science Foundation of Colleges and Universities in Jiangsu Province 16KJB360001Natural Science Foundation of Colleges and Universities in Jiangsu Province 17KJA360002Natural Science Foundation of Jiangsu Province BK20141467Natural Science Foundation of Jiangsu Province BK20161045
6 · The paper itself

Abstract

Chronic inflammation and oxidant/antioxidant imbalance play a prominent role in inflammatory lung diseases. 2-Hydroxymethyl anthraquinone (HMA), an anthraquinone derivative found in Hedyotis diffusa Willd, has been reported to have broad-spectrum anti-inflammatory effects; the present study was conducted to investigate the protective effect of HMA in LPS-induced acute lung injury (ALI) and to explore its potential molecular mechanisms. The results showed that HMA remarkably attenuated LPS-induced pulmonary edema, myeloperoxidase activity, and inflammatory cytokine production. Besides, HMA showed significant antioxidative activity; it raised the levels of SOD and GSH and depleted the MDA level in serum of ALI mice. In vitro, HMA suppressed the production NO, TGF-β1, TNF-α, IL-6, and IL-1β in LPS-stimulated RAW 264.7 macrophage cells. The western blot analysis showed that TLR4 expression and the activation of NF-κB were antagonized by HMA. Moreover, addition of exogenous NF-κB inhibitor BAY11-7082 weakened the inhibitory effects of HMA in inflammatory cytokines and ROS production. Taken together, these findings provide the first experimental evidence supporting that HMA has protective effects on LPS-induced inflammation, which is mediated by TLR4-NF-κB pathway.

Indexed as

Acute Lung InjuryAnimalsAnthraquinonesAntioxidantsHedyotisInflammationLipopolysaccharidesMiceNF-kappa BProtective AgentsPulmonary EdemaRAW 264.7 CellsSignal TransductionToll-Like Receptor 4AnthraquinonesAntioxidantsLipopolysaccharidesNF-kappa BProtective AgentsToll-Like Receptor 4Acute lung injuryAntioxidantHMANF-κBTLR4

Identifiers

PMID30143934
OpenAlexW2888160243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.